

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Amendments to the Claims:**

1-11. (canceled)

12. (currently amended) A method for the treatment of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity to a patient in need thereof, said inhibitor being selected from one or more of an anti-CSF-1 antibody and a CSF-1-binding fragment of an anti-CSF-1 antibody.

13. (withdrawn) The method according to claim 12, wherein the inhibitor is a nucleic acid.

14. (withdrawn) method according to claim 12, wherein the inhibitor is a small molecule (NCE).

15. (cancelled)

16. (currently amended) The method according to claim ~~15~~ 12, wherein the antibody or antibody fragment is monoclonal, polyclonal, chimeric, humanized, or bispecific.

17. (currently amended) The method according to claim ~~15~~ 12 wherein the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or CSF-1 binding fragment.

18. (currently amended) The method according to claim ~~15~~ 12 wherein the antibody or antibody fragment is conjugated to one or more effector molecule(s).

19. (currently amended) The method according to claim ~~15~~ 12 wherein the antibody or antibody fragment binds to CSF-1.

20. (withdrawn) The method according to claim 15 wherein the antibody or antibody fragment binds to CSF-1R.

21. (previously presented) The method according to claim 12 wherein the inflammatory bowel disease is Crohn's disease.

22. (previously presented) The method according to claim 12 wherein the inflammatory bowel disease is ulcerative colitis.

23. (previously presented) The method according to claim 12 wherein the inhibitor of CSF-1 activity is administered in combination with one or more other therapeutically active compounds.

24. (previously presented) The method according to claim 23 wherein the other therapeutically active compound is another anti-IBD therapeutic agent.

25. (previously presented) The method according to claim 23 wherein the other therapeutically active compound is an anti-cancer therapeutic agent.